Knowledge

Hapten

Source 📝

492:
method of hapten conjugation is that there is automated analysis of sample and the testing of sample interactions can be determined in free solution. This method of hapten-protein conjugation is exceptionally effective with conjugates of low epitope densities, where it is otherwise very challenging by the use of other methods to determine their electrical or ionic mobility.
329:. However, to achieve the best and most desirable results, many factors are needed to be taken into the design of hapten conjugates. These include the method of hapten conjugation, the type of carrier used and the hapten density. Variations in these factors could lead to different strengths of immune response toward the newly formed antigenic determinant. 345:), either by itself, or it can be converted to a protein-reactive species for example by air oxidation or cutaneous metabolism. Haptens become fastened to a carrier molecule by a covalent bond. Depending on the haptens being used, other factors in considering the carrier proteins could include their in vivo toxicity, commercial availability and cost. 138:, the small-molecule hapten may also be able to bind to the antibody, but it will usually not initiate an immune response; usually only the hapten-carrier adduct can do this. Sometimes the small-molecule hapten can even block immune response to the hapten-carrier adduct by preventing the adduct from binding to the antibody, a process called 559:
Hapten-specific antibodies are used in broad area of different immunoassays, immunobiosensor technologies and immunoaffinity chromatography purification columns; those antibodies could be used to detect small environmental contaminants, drugs of abuse, vitamins, hormones, metabolites, food toxins and
387:
Most common reaction mechanisms forming covalent bonds and predicted to be involved in sensitization are nucleophilic substitution on a saturated centre, nucleophilic substitution on an unsaturated centre and nucleophilic addition. Other reactions are also possible, such as electrophilic substitution
300:
to crosslink these molecules to carrier proteins suitable for immune recognition. Notably, detection of such small molecules in tissues requires the tissue to be glutaraldehyde-fixed, as the glutaraldehyde covalent-linkage on the molecule of interest often forms a portion of the antibody recognized
491:
with a very high separation capacity. There are numerous advantages to using HPCE as a technique to investigate certain conjugates such as only requiring minute sample sizes (nl). In addition, the sample used does not need to be pure and no type of radiolabeling is needed. A great benefit to this
535:
Haptens are widely used in immunology and related fields. Sensitizing chemicals can cause different forms of allergy, allergic contact dermatitis, or sensitization of the respiratory tract. Interestingly, discrete types of chemicals induce divergent immune responses: contact allergens provoke
115:. The second elicitation phase where the hapten is applied to a different skin area starts with activation of effector T cells followed by T cell-mediated tissue damage and antibody-mediated immune responses. Haptens initially activate innate immune responses by complex mechanisms involving 99:. It consists of two phases: sensitization and elicitation. The sensitization phase where the hapten is applied to the skin for the first time is characterized by the activation of innate immune responses, including migration of dendritic cells to the lymph nodes, priming antigen-specific 744:
Sakamoto, Eri; Katahira, Yasuhiro; Mizoguchi, Izuru; Watanabe, Aruma; Furusaka, Yuma; Sekine, Ami; Yamagishi, Miu; Sonoda, Jukito; Miyakawa, Satomi; Inoue, Shinya; Hasegawa, Hideaki; Yo, Kazuyuki; Yamaji, Fumiya; Toyoda, Akemi; Yoshimoto, Takayuki (12 January 2023).
555:
tests for skin sensitization, hazard identification, and potency evaluation on different drug and cosmetic components are highly preferred in early product development. The ability of a drug to act as a hapten is a clear indication of potential immunogenicity.
433:: A group of compounds with a general formula of R-N=C=N-R′, where R and R′ are either aliphatic (i.e., diethylcarbodiimide) or aromatic (i.e., diphenylcarbodiimide). Conjugation using a carbodiimide requires the presence of α or ɛ-amino and a 441:
residue of the carrier protein while the carboxyl group comes from the hapten. The exact mechanism for this reaction is still unknown. However, two pathways are proposed. The first postulates that an intermediate that can react with an
510:
response. In inhibition, free hapten molecules bind with antibodies toward that molecule without causing the immune response, leaving fewer antibodies left to bind to the immunogenic hapten-protein adduct. An example of a
426:
are to aid the conjugation of haptens to their carriers. The extent of cross-linkage is dependent upon the hapten/carrier to coupling agent ratio, hapten/carrier concentration and the temperature, pH of the environment.
161:-type molecule, which then reacts with skin proteins to form hapten adducts. After a second exposure, the proliferated T-cells become activated, generating an immune reaction that produces typical blisters of a 396:
While selecting a suitable method for hapten conjugation, functional groups on the hapten and its carrier must be identified. Depending on the groups present, one of the two main strategies could be employed:
1009:"Studies on the immune response and preparation of antibodies against a large panel of conjugated neurotransmitters and biogenic amines: specific polyclonal antibody response and tolerance" 468:
of the reaction. Higher pH would give rise to more Schiff base intermediates and subsequently lead to the increase in hapten conjugates' number and size. Overall, cross-linkage involving
956:
Tagliaferro, P; Tandler, C.J; Ramos, A.J; Pecci Saavedra, J; Brusco, A (1997). "Immunofluorescence and glutaraldehyde fixation. A new procedure based on the Schiff-quenching method".
57:
by itself. The mechanisms of absence of immune response may vary and involve complex immunological interactions, but can include absent or insufficient co-stimulatory signals from
368:
is often to bind to xenobiotics via its substrate-binding pockets and remove the invading chemical from the circulation or tissue, thus acting as a detoxification mechanism.
1289:
Frøkiaer, H.; Sørensen, H.; Sørensen, J. C.; Sørensen, S. (1995-11-24). "Optimization of hapten-protein conjugation by high-performance capillary electrophoresis".
180:
A lot of haptens are comprised in different kinds of drugs, pesticides, hormones, food toxins etc. Most important factor is the molecular mass, which is <1000
293: 364:(HSA) is often the model protein of choice for protein-binding assays. This is a well-characterized protein, and the role of albumin in blood and tissues 1533: 831:"Defining the complementarities between antibodies and haptens to refine our understanding and aid the prediction of a successful binding interaction" 1404:
Divkovic, Maja; Basketter, David A.; Gilmour, Nicola; Panico, Maria; Dell, Anne; Morris, Howard R.; Pease, Camilla K. Smith (2003-01-01).
341:
residues in the reactive side chains to conjugate with the haptens. For protein haptenation to occur, hapten must be electron deficient (
829:
Al Qaraghuli, Mohammed M.; Palliyil, Soumya; Broadbent, Gillian; Cullen, David C.; Charlton, Keith A.; Porter, Andrew J. (2015-10-24).
484: 620:"Hapten-Induced Contact Hypersensitivity, Autoimmune Reactions, and Tumor Regression: Plausibility of Mediating Antitumor Immunity" 256:
Antibodies have successfully been raised against endogenous & unreactive small molecules such as some neurotransmitters (e.g.
1526: 523:) of the entire dextran complex, which is enough to bind anti-dextran antibodies, but insufficient to result in the formation of 1357:
Hopkins, Josephine E.; Naisbitt, Dean J.; Kitteringham, Neil R.; Dearman, Rebecca J.; Kimber, Ian; Park, B. Kevin (2005-02-01).
1344: 1273: 693: 1211:
Bauminger, Sara; Wilchek, Meir (1980). "[7] the use of carbodiimides in the preparation of immunizing conjugates".
902: 1359:"Selective Haptenation of Cellular or Extracellular Protein by Chemical Allergens: Association with Cytokine Polarization" 162: 120: 1519: 544:, which could be very suitable for modeling how the immune response is polarized towards different types of antigens. 1228: 1080: 1865: 487:(HPCE) is an alternative method in optimizing hapten-protein conjugation. HPCE is predominantly used in separating 1860: 1156:"Hapten-protein binding: from theory to practical application in the in vitro prediction of skin sensitization" 418:
This method mainly applies to nonreactive haptens. Agents with at least two chemically reactive groups such as
1803: 1106:"Synthesis and Characterization of Hapten−Protein Conjugates for Antibody Production against Small Molecules" 87:
Haptens applied on skin, when conjugate with a carrier, could induce contact hypersensitivity, which is a
65: 464:
or Michael-type double bond addition products. The yield of conjugates can be controlled by varying the
1689: 1333:
Affinity probe capillary electrophoresis evaluation of aptamer binding to Campylobacter jejuni bacteria
1008: 709:
Shreder, Kevin (March 2000). "Synthetic Haptens as Probes of Antibody Response and Immunorecognition".
69: 1452: 1331:
Stratis-Cullum, D., McMasters, Sun, Pellegrino, Paul M, & U.S. Army Research Laboratory. (2009).
507: 1511: 1505: 541: 88: 1869: 1627: 537: 58: 17: 1962: 1891: 1609: 1545: 1838: 1694: 1672: 371:
Although proteins are mostly employed for hapten conjugation, synthetic polypeptides such as
322: 116: 747:"Chemical- and Drug-Induced Allergic, Inflammatory, and Autoimmune Diseases Via Haptenation" 1855: 1788: 1699: 1623: 1406:"Protein–Hapten Binding: Challenges and Limitations for In Vitro Skin Sensitization Assays" 1104:
Singh, K. V.; Kaur, Jasdeep; Varshney, Grish C.; Raje, Manoj; Suri, C. Raman (2004-01-01).
218:
in certain individuals. This also appears to be the mechanism by which the anesthetic gas
172:, which is caused by nickel metal ions penetrating the skin and binding to skin proteins. 8: 1967: 1915: 1850: 1833: 1667: 1585: 949: 361: 289: 215: 200: 196: 1154:
Divkovic, Maja; Pease, Camilla K.; Gerberick, G. Frank; Basketter, David A. (May 2005).
1735: 1433: 1193: 1036: 989: 938: 865: 830: 781: 746: 646: 619: 150: 1220: 969: 1783: 1549: 1480: 1472: 1468: 1425: 1386: 1378: 1335:(ARL-TR (Aberdeen Proving Ground, Md.); 5015). Adelphi, MD: Army Research Laboratory. 1314: 1306: 1302: 1269: 1253: 1234: 1224: 1185: 1177: 1172: 1155: 1133: 1125: 1086: 1076: 1040: 1028: 1024: 981: 973: 930: 922: 918: 870: 852: 805: 786: 768: 726: 689: 651: 372: 250: 79:, who also pioneered the use of synthetic haptens to study immunochemical phenomena. 1437: 993: 942: 1903: 1843: 1815: 1810: 1778: 1765: 1755: 1501: 1464: 1417: 1370: 1298: 1261: 1216: 1197: 1167: 1117: 1068: 1020: 965: 914: 860: 842: 776: 758: 718: 641: 631: 412:. This method of conjugation is spontaneous and no cross-linking agents are needed. 325:. They are also vital in the development of sensitive quantitative and qualitative 231: 192: 76: 1265: 313:
Due to their nature and properties, hapten-carrier adducts have been essential in
1798: 1072: 54: 46: 1825: 1770: 1711: 1631: 1604: 1358: 524: 473: 469: 457: 453: 434: 423: 405: 297: 237:
Other haptens that are commonly used in molecular biology applications include
169: 96: 42: 38: 847: 1956: 1793: 1682: 1476: 1429: 1382: 1310: 1181: 1129: 1105: 977: 926: 856: 772: 488: 281: 181: 153:. When absorbed through the skin from a poison ivy plant, urushiol undergoes 104: 763: 594: 214:, a blood pressure-lowering drug that occasionally can produce drug-induced 1760: 1745: 1740: 1677: 1575: 1484: 1390: 1189: 1137: 1090: 1032: 934: 874: 790: 730: 722: 655: 430: 419: 342: 326: 124: 100: 1421: 1318: 1238: 985: 636: 450:, the main side product of the reaction at high temperature, has occurred. 1451:
Sheedy, Claudia; Roger MacKenzie, C.; Hall, J. Christopher (2007-07-01).
461: 321:
and antibodies. They are important in the purification and production of
246: 238: 211: 112: 1405: 1374: 1883: 1636: 1542: 520: 409: 338: 314: 285: 273: 227: 207: 131: 1121: 337:
In general, carrier proteins should be immunogenic and contain enough
75:
The concept of haptens emerged from the work of Austrian immunologist
1941: 1646: 1541: 955: 516: 357: 261: 257: 223: 219: 154: 27:
Molecule which triggers an immune response when attached to a carrier
1931: 1716: 1704: 1662: 1616: 1580: 828: 376: 349: 318: 265: 146: 1356: 1067:. Methods in Molecular Medicine. Vol. 138. pp. 167–182. 1063:
Lemus, Ranulfo; Karol, Meryl H. (2008). "Conjugation of Haptens".
1936: 1750: 1599: 1570: 1453:"Isolation and affinity maturation of hapten-specific antibodies" 1345:
Promiten, drug information from the Swedish official drug catalog
743: 574: 353: 302: 277: 188: 158: 50: 1288: 1254:"Conjugation of Peptides to Carrier Proteins via Glutaraldehyde" 1908: 1896: 1641: 1153: 242: 135: 108: 92: 1403: 686:
The Specificity of Serological Reactions, 2nd Edition, revised
446:
is formed. The second stating that a rearrangement of an acyl
569: 540:
responses, whereas respiratory allergens stimulate selective
472:
is very stable. However, immunized animals tend to recognize
443: 438: 317:. They have been used to evaluate the properties of specific 82: 1007:
Huisman, Han; Wynveen, Paul; Setter, Peter W. (2010-02-06).
157:
in the skin cells to generate the actual hapten, a reactive
447: 388:(diazonium salts), radical reactions, and ionic reactions. 269: 506:
Hapten inhibition or "semi-hapten" is the inhibition of a
1450: 1215:. Methods in Enzymology. Vol. 70. pp. 151–159. 404:
Used when hapten is a chemical reactive molecule such as
168:
Other example of a hapten-mediated contact dermatitis is
465: 1410:
Journal of Toxicology: Cutaneous and Ocular Toxicology
53:; the carrier may be one that also does not elicit an 1103: 103:, and the generation of antigen-specific effector or 1006: 1260:. Springer Protocols Handbooks. pp. 679–687. 907:Current Opinion in Allergy and Clinical Immunology 1954: 1210: 391: 382: 49:only when attached to a large carrier such as a 1527: 1058: 1056: 1054: 1052: 1050: 456:: This method works by the reaction between 683: 668: 617: 482:High performance capillary electrophoresis: 72:(IBD) to induce autoimmune-like responses. 1534: 1520: 1062: 485:High performance capillary electrophoresis 83:Immune reaction on a hapten-carrier adduct 1504:at the U.S. National Library of Medicine 1171: 1047: 864: 846: 780: 762: 645: 635: 437:. The amino group usually comes from the 671:The Specificity of Serological Reactions 900: 708: 14: 1955: 1251: 889:The Specificity of Serologic Reactions 618:Erkes, Dan; Selvan, Senthamil (2014). 175: 1515: 1149: 1147: 476:'s cross-linking bridges as epitopes. 416:Intermediary molecules cross-linkage: 308: 595:"Hapten | biochemistry | Britannica" 501: 226:, as well as the mechanism by which 145:A well-known example of a hapten is 121:damage-associated molecular patterns 803: 163:urushiol-induced contact dermatitis 24: 1144: 187:The first researched haptens were 25: 1979: 1495: 1213:Immunochemical Techniques, Part A 901:Pichler, Werner J. (2003-08-01). 673:. Cambridge: Harvard Univ. Press. 348:The most common carriers include 1469:10.1016/j.biotechadv.2007.02.003 1173:10.1111/j.0105-1873.2005.00683.x 1025:10.1111/j.1471-4159.2009.06492.x 919:10.1097/00130832-200308000-00003 527:and resultant immune responses. 89:type IV delayed hypersensitivity 64:Haptens have been used to study 1444: 1397: 1363:Chemical Research in Toxicology 1350: 1338: 1325: 1282: 1252:Carter, John (1 January 1996). 1245: 1204: 1097: 1000: 958:Journal of Neuroscience Methods 894: 887:Based on K. Landsteiner, 1962, 519:, which is a small fraction (1 496: 1861:Immunoglobulin class switching 1258:The Protein Protocols Handbook 881: 822: 797: 737: 702: 688:. Courier Dover Publications. 677: 662: 624:Journal of Immunology Research 611: 587: 402:Spontaneous chemical reaction: 230:-class drugs cause autoimmune 191:and its carboxyl derivatives ( 149:, which is the toxin found in 13: 1: 1266:10.1007/978-1-60327-259-9_117 1221:10.1016/s0076-6879(80)70046-0 1065:Allergy Methods and Protocols 970:10.1016/s0165-0270(97)00126-x 580: 392:Methods of hapten conjugation 383:Mechanisms of protein binding 222:can cause a life-threatening 1303:10.1016/0021-9673(95)00642-X 1073:10.1007/978-1-59745-366-0_14 130:Once the body has generated 68:(ACD) and the mechanisms of 7: 1291:Journal of Chromatography A 964:(2). Elsevier BV: 191–197. 903:"Drug-induced autoimmunity" 563: 530: 332: 66:allergic contact dermatitis 37:, meaning “to fasten”) are 10: 1984: 1690:Polyclonal B cell response 684:Landsteiner, Karl (1990). 669:Landsteiner, Karl (1945). 560:environmental pollutants. 460:with amine groups to form 70:inflammatory bowel disease 1924: 1882: 1824: 1725: 1655: 1563: 1556: 1013:Journal of Neurochemistry 848:10.1186/s12896-015-0217-x 508:type III hypersensitivity 1506:Medical Subject Headings 1347:Last updated: 2005-02-17 810:pubchem.ncbi.nlm.nih.gov 206:Some haptens can induce 59:antigen-presenting cells 33:(derived from the Greek 764:10.3390/biology12010123 538:type I hypersensitivity 210:disease. An example is 111:and antibody-secreting 1804:Tolerance in pregnancy 1546:adaptive immune system 1457:Biotechnology Advances 1110:Bioconjugate Chemistry 723:10.1006/meth.1999.0929 375:, polysaccharides and 117:inflammatory cytokines 1839:Somatic hypermutation 1673:Polyclonal antibodies 1668:Monoclonal antibodies 1422:10.1081/CUS-120020382 323:monoclonal antibodies 284:), amino acids (e.g. 91:reaction mediated by 1856:Junctional diversity 1624:Antigen presentation 379:could also be used. 373:Poly-L-glutamic acid 134:to a hapten-carrier 1851:V(D)J recombination 1834:Affinity maturation 1586:Antigenic variation 637:10.1155/2014/175265 362:Human serum albumin 294:5-methoxytryptophan 290:5-hydroxytryptophan 216:lupus erythematosus 201:p-aminobenzoic acid 176:Examples of haptens 1160:Contact Dermatitis 599:www.britannica.com 309:Hapten conjugation 1950: 1949: 1878: 1877: 1628:professional APCs 1375:10.1021/tx049688+ 1275:978-0-89603-338-2 1122:10.1021/bc034158v 835:BMC Biotechnology 695:978-0-486-66203-9 630:. Hindawi: 1–28. 542:type II responses 502:Hapten inhibition 360:and many others. 140:hapten inhibition 16:(Redirected from 1975: 1844:Clonal selection 1816:Immune privilege 1811:Immunodeficiency 1766:Cross-reactivity 1756:Hypersensitivity 1561: 1560: 1536: 1529: 1522: 1513: 1512: 1489: 1488: 1448: 1442: 1441: 1401: 1395: 1394: 1354: 1348: 1342: 1336: 1329: 1323: 1322: 1286: 1280: 1279: 1249: 1243: 1242: 1208: 1202: 1201: 1175: 1151: 1142: 1141: 1101: 1095: 1094: 1060: 1045: 1044: 1004: 998: 997: 953: 947: 946: 898: 892: 885: 879: 878: 868: 850: 826: 820: 819: 817: 816: 801: 795: 794: 784: 766: 741: 735: 734: 706: 700: 699: 681: 675: 674: 666: 660: 659: 649: 639: 615: 609: 608: 606: 605: 591: 547:In allergology, 525:immune complexes 513:hapten inhibitor 232:hemolytic anemia 77:Karl Landsteiner 21: 1983: 1982: 1978: 1977: 1976: 1974: 1973: 1972: 1953: 1952: 1951: 1946: 1920: 1874: 1820: 1799:Clonal deletion 1727: 1721: 1651: 1552: 1540: 1498: 1493: 1492: 1449: 1445: 1402: 1398: 1355: 1351: 1343: 1339: 1330: 1326: 1287: 1283: 1276: 1250: 1246: 1231: 1209: 1205: 1152: 1145: 1102: 1098: 1083: 1061: 1048: 1005: 1001: 954: 950: 899: 895: 886: 882: 827: 823: 814: 812: 802: 798: 742: 738: 707: 703: 696: 682: 678: 667: 663: 616: 612: 603: 601: 593: 592: 588: 583: 566: 533: 504: 499: 394: 385: 335: 311: 178: 123:(DAMP), or the 97:dendritic cells 85: 55:immune response 47:immune response 39:small molecules 28: 23: 22: 15: 12: 11: 5: 1981: 1971: 1970: 1965: 1948: 1947: 1945: 1944: 1939: 1934: 1928: 1926: 1922: 1921: 1919: 1918: 1913: 1912: 1911: 1901: 1900: 1899: 1888: 1886: 1880: 1879: 1876: 1875: 1873: 1872: 1863: 1858: 1853: 1848: 1847: 1846: 1841: 1830: 1828: 1826:Immunogenetics 1822: 1821: 1819: 1818: 1813: 1808: 1807: 1806: 1801: 1796: 1791: 1786: 1774: 1773: 1771:Co-stimulation 1768: 1763: 1758: 1753: 1748: 1743: 1738: 1731: 1729: 1723: 1722: 1720: 1719: 1714: 1712:Immune complex 1708: 1707: 1702: 1697: 1692: 1687: 1686: 1685: 1680: 1675: 1670: 1659: 1657: 1653: 1652: 1650: 1649: 1644: 1639: 1634: 1632:Dendritic cell 1620: 1619: 1614: 1613: 1612: 1610:Conformational 1607: 1596: 1595: 1590: 1589: 1588: 1583: 1578: 1567: 1565: 1558: 1554: 1553: 1539: 1538: 1531: 1524: 1516: 1510: 1509: 1497: 1496:External links 1494: 1491: 1490: 1463:(4): 333–352. 1443: 1416:(1–2): 87–99. 1396: 1369:(2): 375–381. 1349: 1337: 1324: 1297:(1–2): 75–81. 1281: 1274: 1244: 1229: 1203: 1166:(4): 189–200. 1143: 1116:(1): 168–173. 1096: 1081: 1046: 1019:(3): 829–841. 999: 948: 913:(4): 249–253. 893: 880: 821: 796: 736: 717:(3): 372–379. 701: 694: 676: 661: 610: 585: 584: 582: 579: 578: 577: 572: 565: 562: 532: 529: 503: 500: 498: 495: 494: 493: 479: 478: 477: 474:glutaraldehyde 470:glutaraldehyde 458:glutaraldehyde 454:Glutaraldehyde 451: 435:carboxyl group 424:glutaraldehyde 413: 393: 390: 384: 381: 350:serum globulin 334: 331: 310: 307: 298:glutaraldehyde 177: 174: 170:nickel allergy 105:memory T cells 84: 81: 26: 9: 6: 4: 3: 2: 1980: 1969: 1966: 1964: 1963:Immune system 1961: 1960: 1958: 1943: 1940: 1938: 1935: 1933: 1930: 1929: 1927: 1923: 1917: 1914: 1910: 1907: 1906: 1905: 1902: 1898: 1895: 1894: 1893: 1890: 1889: 1887: 1885: 1881: 1871: 1867: 1864: 1862: 1859: 1857: 1854: 1852: 1849: 1845: 1842: 1840: 1837: 1836: 1835: 1832: 1831: 1829: 1827: 1823: 1817: 1814: 1812: 1809: 1805: 1802: 1800: 1797: 1795: 1794:Clonal anergy 1792: 1790: 1787: 1785: 1782: 1781: 1780: 1776: 1775: 1772: 1769: 1767: 1764: 1762: 1759: 1757: 1754: 1752: 1749: 1747: 1744: 1742: 1739: 1737: 1733: 1732: 1730: 1724: 1718: 1715: 1713: 1710: 1709: 1706: 1703: 1701: 1698: 1696: 1693: 1691: 1688: 1684: 1683:Microantibody 1681: 1679: 1676: 1674: 1671: 1669: 1666: 1665: 1664: 1661: 1660: 1658: 1654: 1648: 1645: 1643: 1640: 1638: 1635: 1633: 1629: 1625: 1622: 1621: 1618: 1615: 1611: 1608: 1606: 1603: 1602: 1601: 1598: 1597: 1594: 1591: 1587: 1584: 1582: 1579: 1577: 1574: 1573: 1572: 1569: 1568: 1566: 1562: 1559: 1555: 1551: 1547: 1544: 1537: 1532: 1530: 1525: 1523: 1518: 1517: 1514: 1507: 1503: 1500: 1499: 1486: 1482: 1478: 1474: 1470: 1466: 1462: 1458: 1454: 1447: 1439: 1435: 1431: 1427: 1423: 1419: 1415: 1411: 1407: 1400: 1392: 1388: 1384: 1380: 1376: 1372: 1368: 1364: 1360: 1353: 1346: 1341: 1334: 1328: 1320: 1316: 1312: 1308: 1304: 1300: 1296: 1292: 1285: 1277: 1271: 1267: 1263: 1259: 1255: 1248: 1240: 1236: 1232: 1230:9780121819705 1226: 1222: 1218: 1214: 1207: 1199: 1195: 1191: 1187: 1183: 1179: 1174: 1169: 1165: 1161: 1157: 1150: 1148: 1139: 1135: 1131: 1127: 1123: 1119: 1115: 1111: 1107: 1100: 1092: 1088: 1084: 1082:9780896038967 1078: 1074: 1070: 1066: 1059: 1057: 1055: 1053: 1051: 1042: 1038: 1034: 1030: 1026: 1022: 1018: 1014: 1010: 1003: 995: 991: 987: 983: 979: 975: 971: 967: 963: 959: 952: 944: 940: 936: 932: 928: 924: 920: 916: 912: 908: 904: 897: 891:, Dover Press 890: 884: 876: 872: 867: 862: 858: 854: 849: 844: 840: 836: 832: 825: 811: 807: 800: 792: 788: 783: 778: 774: 770: 765: 760: 756: 752: 748: 740: 732: 728: 724: 720: 716: 712: 705: 697: 691: 687: 680: 672: 665: 657: 653: 648: 643: 638: 633: 629: 625: 621: 614: 600: 596: 590: 586: 576: 573: 571: 568: 567: 561: 557: 554: 550: 545: 543: 539: 536:preferential 528: 526: 522: 518: 514: 509: 490: 489:carbohydrates 486: 483: 480: 475: 471: 467: 463: 459: 455: 452: 449: 445: 440: 436: 432: 429: 428: 425: 421: 417: 414: 411: 407: 403: 400: 399: 398: 389: 380: 378: 374: 369: 367: 363: 359: 355: 351: 346: 344: 343:electrophilic 340: 330: 328: 324: 320: 316: 306: 304: 299: 295: 291: 287: 283: 282:noradrenaline 279: 275: 271: 267: 263: 259: 254: 252: 251:dinitrophenol 248: 244: 240: 235: 233: 229: 225: 221: 217: 213: 209: 204: 202: 198: 194: 190: 185: 183: 173: 171: 166: 164: 160: 156: 152: 148: 143: 141: 137: 133: 128: 126: 122: 118: 114: 110: 106: 102: 101:naive T cells 98: 94: 90: 80: 78: 73: 71: 67: 62: 60: 56: 52: 48: 44: 40: 36: 32: 19: 1761:Inflammation 1746:Alloimmunity 1741:Autoimmunity 1726:Immunity vs. 1678:Autoantibody 1592: 1576:Superantigen 1460: 1456: 1446: 1413: 1409: 1399: 1366: 1362: 1352: 1340: 1332: 1327: 1294: 1290: 1284: 1257: 1247: 1212: 1206: 1163: 1159: 1113: 1109: 1099: 1064: 1016: 1012: 1002: 961: 957: 951: 910: 906: 896: 888: 883: 838: 834: 824: 813:. Retrieved 809: 799: 754: 750: 739: 714: 710: 704: 685: 679: 670: 664: 627: 623: 613: 602:. Retrieved 598: 589: 558: 552: 548: 546: 534: 512: 505: 497:Clinical use 481: 462:Schiff bases 431:Carbodiimide 420:carbodiimide 415: 401: 395: 386: 370: 365: 347: 336: 327:immunoassays 312: 296:), by using 255: 236: 205: 186: 179: 167: 144: 139: 129: 125:inflammasome 113:plasma cells 86: 74: 63: 34: 30: 29: 1884:Lymphocytes 1543:Lymphocytic 410:isocyanates 247:digoxigenin 239:fluorescein 212:hydralazine 1968:Immunology 1957:Categories 1925:Substances 1789:Peripheral 1777:Inaction: 1656:Antibodies 1637:Macrophage 1550:complement 815:2023-01-23 806:"Urushiol" 757:(1): 123. 604:2023-01-23 581:References 521:kilodalton 406:anhydrides 339:amino acid 315:immunology 286:tryptophan 274:tryptamine 228:penicillin 208:autoimmune 151:poison ivy 132:antibodies 1942:Cytolysin 1932:Cytokines 1779:Tolerance 1728:tolerance 1647:Immunogen 1477:0734-9750 1430:0731-3829 1383:0893-228X 1311:0021-9673 1182:0105-1873 1130:1043-1802 1041:205621520 978:0165-0270 927:1528-4050 857:1472-6750 841:(1): 99. 804:PubChem. 773:2079-7737 553:in silico 517:dextran 1 377:liposomes 358:ovalbumin 262:glutamate 258:serotonin 224:hepatitis 220:halothane 155:oxidation 1892:Cellular 1736:Immunity 1734:Action: 1717:Paratope 1705:Idiotype 1695:Allotype 1663:Antibody 1617:Mimotope 1581:Allergen 1564:Antigens 1557:Lymphoid 1485:17383141 1438:72917520 1391:15720145 1190:16191014 1138:14733597 1091:18612607 1033:19912471 994:19400487 943:46521947 935:12865767 875:26498921 791:36671815 731:10694458 656:24949488 564:See also 549:in vitro 531:Research 354:albumins 333:Carriers 319:epitopes 266:dopamine 147:urushiol 1937:Opsonin 1916:NK cell 1904:Humoral 1784:Central 1751:Allergy 1700:Isotype 1600:Epitope 1571:Antigen 1502:Haptens 1319:8520687 1239:6999295 1198:9713648 986:9489897 866:4619568 782:9855847 751:Biology 711:Methods 647:4052058 575:Antigen 366:in vivo 303:epitope 278:glycine 260:(5HT), 189:aniline 159:quinone 109:B cells 93:T cells 51:protein 35:haptein 31:Haptens 18:Haptens 1909:B cell 1897:T cell 1642:B cell 1605:Linear 1593:Hapten 1508:(MeSH) 1483:  1475:  1436:  1428:  1389:  1381:  1317:  1309:  1272:  1237:  1227:  1196:  1188:  1180:  1136:  1128:  1089:  1079:  1039:  1031:  992:  984:  976:  941:  933:  925:  873:  863:  855:  789:  779:  771:  729:  692:  654:  644:  249:, and 243:biotin 199:, and 136:adduct 43:elicit 1434:S2CID 1194:S2CID 1037:S2CID 990:S2CID 939:S2CID 570:Toxin 444:amine 439:lysyl 41:that 1548:and 1481:PMID 1473:ISSN 1426:ISSN 1387:PMID 1379:ISSN 1315:PMID 1307:ISSN 1270:ISBN 1235:PMID 1225:ISBN 1186:PMID 1178:ISSN 1134:PMID 1126:ISSN 1087:PMID 1077:ISBN 1029:PMID 982:PMID 974:ISSN 931:PMID 923:ISSN 871:PMID 853:ISSN 787:PMID 769:ISSN 727:PMID 690:ISBN 652:PMID 628:2014 448:urea 408:and 270:GABA 107:and 95:and 1870:HLA 1866:MHC 1465:doi 1418:doi 1371:doi 1299:doi 1295:717 1262:doi 1217:doi 1168:doi 1118:doi 1069:doi 1021:doi 1017:112 966:doi 915:doi 861:PMC 843:doi 777:PMC 759:doi 719:doi 642:PMC 632:doi 515:is 422:or 203:). 45:an 1959:: 1630:: 1479:. 1471:. 1461:25 1459:. 1455:. 1432:. 1424:. 1414:22 1412:. 1408:. 1385:. 1377:. 1367:18 1365:. 1361:. 1313:. 1305:. 1293:. 1268:. 1256:. 1233:. 1223:. 1192:. 1184:. 1176:. 1164:53 1162:. 1158:. 1146:^ 1132:. 1124:. 1114:15 1112:. 1108:. 1085:. 1075:. 1049:^ 1035:. 1027:. 1015:. 1011:. 988:. 980:. 972:. 962:77 960:. 937:. 929:. 921:. 909:. 905:. 869:. 859:. 851:. 839:15 837:. 833:. 808:. 785:. 775:. 767:. 755:12 753:. 749:. 725:. 715:20 713:. 650:. 640:. 626:. 622:. 597:. 466:pH 356:, 352:, 305:. 292:, 288:, 280:, 276:, 272:, 268:, 264:, 253:. 245:, 241:, 234:. 197:m- 195:, 193:o- 184:. 182:Da 165:. 142:. 127:. 119:, 61:. 1868:/ 1626:/ 1535:e 1528:t 1521:v 1487:. 1467:: 1440:. 1420:: 1393:. 1373:: 1321:. 1301:: 1278:. 1264:: 1241:. 1219:: 1200:. 1170:: 1140:. 1120:: 1093:. 1071:: 1043:. 1023:: 996:. 968:: 945:. 917:: 911:3 877:. 845:: 818:. 793:. 761:: 733:. 721:: 698:. 658:. 634:: 607:. 551:/ 20:)

Index

Haptens
small molecules
elicit
immune response
protein
immune response
antigen-presenting cells
allergic contact dermatitis
inflammatory bowel disease
Karl Landsteiner
type IV delayed hypersensitivity
T cells
dendritic cells
naive T cells
memory T cells
B cells
plasma cells
inflammatory cytokines
damage-associated molecular patterns
inflammasome
antibodies
adduct
urushiol
poison ivy
oxidation
quinone
urushiol-induced contact dermatitis
nickel allergy
Da
aniline

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.

↑